Abstract
Abstract 1041
Several studies suggest that subnormal vitamin D levels may be prognostic in a number of malignancies, including non Hodgkin lymphoma, prostate, breast, colon and lung cancer. However, no studies have evaluated the impact of subnormal vitamin D levels on treatment outcome in AML. Vitamin D levels were evaluated in 97 consecutive newly diagnosed similarly treated patients with AML (excluding AML M3). There were 50 (52%) males and 47 (48%) females with a median age of 60 years (range 19–91). The median white blood cell (WBC) count at diagnosis was 18×109/L (range 0.57–555.23). Karyotype was favorable in 11%, intermediate in 50%, adverse in 23%, of unknown significance in 11% and not available in 5%. A total of 74 patients (76%) had de novo AML. Albumin levels were subnormal (<3.5g/dl) in 33 (34%) patients and normal (≥3.5g/dl) in 64 (66%) patients. Body mass index (BMI) was calculated on all patients, normal weight (BMI 18–24.9) 33 (32%) patients, overweight (BMI 25–29.9) 34 (35%) patients, obese (BMI 30–34.9) 16 (16%) and very obese (BMI ≥35) 15 (15%) patients. Induction consisted of cytarabine (100mg/m2 × 7 days), daunorubicin (90mg/m2 for <60 and 60mg/m2, for ≥60 × 3 days) and etoposide (100mg/m2 × 3 days) (ADE 7+3+3).
No relevant conflicts of interest to declare.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/116/21/10.1182_blood.v116.21.1041.1041/3/m_permbld2009abs02.jpeg?Expires=1724859017&Signature=Z5QwLAVDPisCzjYV5a6Xa3BDLZG5Y5js47CE-5UHgadNadK5Z0ayeR1Zoo~-bshdPkCOXYNLwHw20-eOHtAzr6WKw0KCwF3O5Ah4yBsWCs-cUMvlouCRlnB5sghc5Unm5s5dnFW2SKCibI8-spyI876jDpVfef4JisEKyUckQnFHHjAi-Nbu7XnD8wIdoHgDZb0BChaz95o~SNoEfJsAS4JPirAjmV5m5QaeOtSphwoGB8mDyCH31ibzrWaYcCgDEpk~nFb0pd54VVHpPh5Wbv9RNXoszMdZdnWR6FUHtNCv97d5ro6vlCbuYbmWh7P0xouOHDMxxb7KoPGewGXNIQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes an abstract that is clinically relevant.
Author notes
Asterisk with author names denotes non-ASH members.